Literature DB >> 8112203

Local tolerability and pharmacokinetic profile of a new transdermal delivery system, diclofenac hydroxyethylpyrrolidine plaster.

A Assandri1, S Canali, C Giachetti.   

Abstract

Flector plaster is a new transdermal delivery system medicated with diclofenac hydroxyethylpyrrolidine salt, an NSAID which seems to possess suitable physiochemical properties for easy release by the plaster matrix for percutaneous absorption. The paper deals with local tolerability and pharmacokinetic (percutaneous absorption) studies carried out both on animals and on volunteers. The results obtained in the safety studies demonstrate the absence of local skin reactions and of sensitization phenomena. The kinetic evidence, obtained at the steady-state, reveals a profile typical of a sustained-release formulation, able to maintain constant plasma levels of the drug up to the next application (12 h). The amount of drug bioavailable for targeting the sites of action is effectively lower than via the oral route, however the estimated absorbed dose of 5-10 mg per application appears to be adequate for the foreseen therapeutic use, taking into account the great advantage in having no undesirable side effects.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8112203

Source DB:  PubMed          Journal:  Drugs Exp Clin Res        ISSN: 0378-6501


  10 in total

Review 1.  Clinical pharmacokinetics of diclofenac. Therapeutic insights and pitfalls.

Authors:  N M Davies; K E Anderson
Journal:  Clin Pharmacokinet       Date:  1997-09       Impact factor: 6.447

2.  Diclofenac induced apoptosis via altering PI3K/Akt/MAPK signaling axis in HCT 116 more efficiently compared to SW480 colon cancer cells.

Authors:  Elif Damla Arisan; Zehragül Ergül; Gülnihal Bozdağ; Özge Rencüzoğulları; Ajda Çoker-Gürkan; Pınar Obakan-Yerlikaya; Deniz Coşkun; Narçin Palavan-Ünsal
Journal:  Mol Biol Rep       Date:  2018-11-08       Impact factor: 2.316

3.  Pharmacokinetics and metabolism of N-(2-hydroxyethyl)-2,5-[14C]-pyrrolidine (HEP, Epolamine) in male healthy volunteers.

Authors:  C Giachetti; A Assandri; G Mautone; E Tajana; B Palumbo; R Palumbo
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1996 Jul-Sep       Impact factor: 2.441

Review 4.  Oral versus topical NSAIDs in rheumatic diseases: a comparison.

Authors:  C A Heyneman; C Lawless-Liday; G C Wall
Journal:  Drugs       Date:  2000-09       Impact factor: 9.546

5.  Diclofenac patches for postoperative shoulder pain.

Authors:  Lennard Funk; Rowena Umaar; Adeyinka Molajo
Journal:  Int J Shoulder Surg       Date:  2008-04

6.  Randomized clinical comparisons of diclofenac concentration in the soft tissues and blood plasma between topical and oral applications.

Authors:  Shin Miyatake; Hiroki Ichiyama; Eiji Kondo; Kazunori Yasuda
Journal:  Br J Clin Pharmacol       Date:  2009-01       Impact factor: 4.335

7.  Diclofenac patch for topical treatment of acute impact injuries: a randomised, double blind, placebo controlled, multicentre study.

Authors:  H G Predel; R Koll; H Pabst; R Dieter; G Gallacchi; B Giannetti; M Bulitta; J L Heidecker; E A Mueller
Journal:  Br J Sports Med       Date:  2004-06       Impact factor: 13.800

Review 8.  Diclofenac epolamine (Flector) patch: evidence for topical activity.

Authors:  Birte Petersen; Stefano Rovati
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

9.  Topical nonsteroidal anti-inflammatory drugs for the treatment of pain due to soft tissue injury: diclofenac epolamine topical patch.

Authors:  David R Lionberger; Michael J Brennan
Journal:  J Pain Res       Date:  2010-11-10       Impact factor: 3.133

Review 10.  Relative efficacy and safety of topical non-steroidal anti-inflammatory drugs for osteoarthritis: a systematic review and network meta-analysis of randomised controlled trials and observational studies.

Authors:  Chao Zeng; Jie Wei; Guanghua Lei; Weiya Zhang; Monica S M Persson; Aliya Sarmanova; Michael Doherty; Dongxing Xie; YiLun Wang; Xiaoxiao Li; Jiatian Li; Huizhong Long
Journal:  Br J Sports Med       Date:  2018-02-07       Impact factor: 13.800

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.